1027 related articles for article (PubMed ID: 27881650)
21. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
22. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
Bouzidi MS; Caval V; Suspène R; Hallez C; Pineau P; Wain-Hobson S; Vartanian JP
J Mol Biol; 2016 Aug; 428(17):3514-28. PubMed ID: 27289067
[TBL] [Abstract][Full Text] [Related]
25. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Davis RW; York IA; Zheng YH
J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
[TBL] [Abstract][Full Text] [Related]
26. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
[TBL] [Abstract][Full Text] [Related]
27. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
28. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
[TBL] [Abstract][Full Text] [Related]
29. Stably expressed APOBEC3F has negligible antiviral activity.
Miyagi E; Brown CR; Opi S; Khan M; Goila-Gaur R; Kao S; Walker RC; Hirsch V; Strebel K
J Virol; 2010 Nov; 84(21):11067-75. PubMed ID: 20702622
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
31. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
32. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
Dang Y; Wang X; Zhou T; York IA; Zheng YH
J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
[TBL] [Abstract][Full Text] [Related]
34. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
35. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
[TBL] [Abstract][Full Text] [Related]
36. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
37. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
Smith JL; Bu W; Burdick RC; Pathak VK
Trends Pharmacol Sci; 2009 Dec; 30(12):638-46. PubMed ID: 19837465
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.
Cadima-Couto I; Saraiva N; Santos AC; Goncalves J
J Neuroimmune Pharmacol; 2011 Jun; 6(2):296-307. PubMed ID: 21279453
[TBL] [Abstract][Full Text] [Related]
39. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
[TBL] [Abstract][Full Text] [Related]
40. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
